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Received September 8, 2010; accepted May 31, 2011AbstractBackground: The Resonance metallic stent has been reported to be sufficient for the management of malignant extrinsic ureteral obstructions
within a 12-month time period. To determine the effectiveness in each specific patient group, we report our experience using the Resonance
stent in the treatment of ureteral obstructions.
Methods: We retrospectively reviewed 20 patients (23 stents) who successfully received the Resonance metallic stents and divided them into
a patent group (n ¼ 19) and an obstructive group (n ¼ 4) according to the treatment results. Twenty-one stents were inserted via cystoscopy or
ureteroscopy in a retrograde fashion. The remaining two were inserted via percutaneous nephrostomy in an antegrade manner. Follow-up serum
creatinine measurements and sonography were performed. The overall ureteral patency rate and the risk of stent failure were evaluated.
Results: The overall ureteral patency rate was 82.6% (19/23). Patients with previous radiotherapy had a 50% (4/8) patency rate which was
significantly lower than non-radiotherapy patients (100%, 15/15, p ¼ 0.028). Malignant obstructions in those other than radiotherapy patients
had a 100% patency rate (5/5). Benign obstructions in those other than radiotherapy patients had a 100% patency rate (10/10). In the radio-
therapy patients, the mode of therapy did not dominate the stent outcome.
Conclusion: Patients with ureteral obstructions can be treated sufficiently with the Resonance metallic stent. Patients who had gynecological
malignancies and received radiotherapy had a higher failure rate after Resonance metallic stent insertion.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Ureteral obstruction caused by malignancy or complicated
benign entities is challenging for urologists, not only due to the
hazard of deteriorating renal function, but also difficulty in
treatment decision making. In patients who have malignant* Corresponding author. Dr. Kun-Yuan Chiu, Division of Urology, Depart-
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doi:10.1016/j.jcma.2011.08.017ureteral obstruction, permanent reconstruction of the obstructed
ureter is not practical because of low life expectancy. In patients
who have complicated benign ureteral obstruction, complicated
and unpredictable surgical procedures usually make patients
hesitate to proceed with intervention. Despite surgical recon-
struction, ureteral stents and percutaneous nephrostomy (PCN)
are common solutions for the treatment of ureteral obstruction.1
A ureteral stent is beneficial for the convenience of patient
activities. The indwelling stent avoids the hazards of catheter
dislodgement and the inconvenience of foreign bodies resulting
from PCN.1,2 Various designs of ureteral stents have been re-
ported, and the results have varied. Polymeric ureteral stentshinese Medical Association. All rights reserved.
Table 1
General information of patients receiving Resonance metallic stents
No. of patients
Age 20 53.9  3.5 (years)
Follow-up 20 5.1  1.0 (months)
Sex
Female 15 75%
Male 5 25%
Stent site
Left 7 35%
Right 10 50%
Bilateral 3 15%
Obstruction site
UPJ 2 10%
Upper 2 10%
Middle 2 10%
Lower 14 70%
Etiology of obstruction
Malignant external compression 7 35%
Benign stenosis 13 65%
Disease etiology
Cervical cancer 6 30%
Colon cancer 3 15%
Endometrial cancer 2 10%
Gastric cancer 1 5%
Cholangial cancer 1 5%
Retroperitoneal leiomyosarcoma 1 5%
Endometriosis 2 10%
UPJO 2 10%
Chronic cystitis 1 5%
Retroperitoneal fibrosis 1 5%
Radiotherapy
Yes 8 40%
No 12 60%
Operation method
Retrograde 18 90%
Antegrade 2 10%
Anesthesia
LA 11 55%
LMA 9 45%
UPJ ¼ ureteropelvic junction; UPJO ¼ ureteropelvic junction obstruction;
LA ¼ local anesthesia; LMA ¼ laryngeal mask anesthesia.
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59% to 84% in malignant extrinsic compression.3,4,5,6 Owing to
the strong compression forces of tumors, ureteral obstruction is
still inevitable in some cases. Metallic mesh stents were devel-
oped for long-term ureteral stents in either malignant extrinsic
compression or intrinsic stenosis, and the patency rate reached
100% in some studies.7,8,9,10 However, once complications
develop (including tumor ingrowth, migration and encrusta-
tion), management is difficult because of the mesh fixation
design.1,2 The Resonance metallic stent (Cook Medical,
Bloomington, IN, USA) has been introduced with a high success
rate in the treatment of malignant extrinsic compression other
than benign intrinsic stenosis.11,12 It is lumenless and solid,
with a spiral design so that it can withstand strong external
compression forces and allow urine passage from its grooves.
The nickelechromiumecobalt metal composition also has
a low stone encrustation rate, resulting in a long period of
maintenance.11,12 However, the patients that might be at high
risk of ureteral stent failure have not been studied. Here, we
report our experience using the Resonancemetallic stent in the
treatment of malignant extrinsic ureteral compression and
benign intrinsic ureteral stenosis.
2. Methods
From January 2008 to August 2009, 22 patients with upper
urinary tract obstruction were treated with Resonance
metallic stent insertion. All patients gave informed consent
before the operation. The definition of obstruction is based
on new onset of dilated renal pelvicalyceal system, from even
ultrasound or computed tomography scan, with or without the
assistance of diuretic renography using nuclear medicine.
The procedures failed in two patients with cervical cancer
after radiotherapy. The other 20 patients (5 male and 15
female) were included. Patients who were 170 cm or taller
were treated with 24e26-cm Resonance metallic stents, and
those less than 170 cm tall were treated with 22e24-cm stents.
All Resonance metallic stents were 6 Fr in diameter. No
patients received balloon dilatation before stent placement.
The patients’ characteristics and disease etiologies are listed in
Table 1. In the malignancy patients, seven out of 14 (5 cervical
cancer, 1 endometrial cancer, and 1 leiomyosarcoma) were in
a disease-free condition, and no definite retroperitoneal tumor
external compression was identified from computed tomog-
raphy before stent insertion.
Resonance metallic stents were inserted using a retro-
grade or antegrade approach. With either approach, a hydro-
philic guidewire must initially be inserted through both ends of
the renal pelvis and the bladder, followed by the placement of
a stent outer sheath along the guidewire. The outer sheath
contained two components: a 6 Fr ureteral dilator and an 8.3
Fr introducer sheath. After removal of the ureteral dilator, the
stent could be pushed through the introducer sheath to obtain
double-coiler positioning. The retrograde approach was per-
formed in patients who already had a ureteral stent or those for
whom ureteroscopy could be accessed under fluoroscopy with
either local or laryngeal mask anesthesia. Antegrade insertionfrom PCN was performed by a radiologist under fluoroscopic
guidance.
All patients received follow-up with transabdominal ultra-
sonography and serum creatinine level measurements until the
end of life or stent failure. Stent patency was defined as
remission of dilated renal pelvicalyceal system or stable
condition without clinical symptoms and improved serum
creatinine level. The diagnosis of radiological remission was
according to the results of sonography recorded by a radiolo-
gist. The stent-related symptoms after procedures were
recorded during outpatient follow-up. Symptoms were graded
on the basis of severity and frequency. Grade 1 was mild and
transient; grade 2 was moderate or persistent; grade 3 was
severe; and grade 4 was life-threatening. Exchange of the
Resonance metallic stents was performed by initially
removing the stents, followed by retrograde ureteroscopy. The
Table 3
Variable comparison between two groups
No. of patients Mean SEM p
Age
Patent 16 50.38 3.74 0.016
Obstructive 4 70.20 4.87
Follow-up (mo)
Patent 16 6.09 1.14 0.017
Obstructive 4 1.29 0.37
Patent
Preoperative Cr 16 1.66 0.20 0.101
Postoperative Cr 16 1.57 0.19
Obstructive
Preoperative Cr 4 2.20 0.47 0.465
Postoperative Cr 4 2.20 0.91
SEM ¼ standard error of mean; Cr ¼ serum creatinine.
462 C.-C. Li et al. / Journal of the Chinese Medical Association 74 (2011) 460e463stent delivery procedures are described above. The exchange
period was indicated at 12 months after the previous stents had
been placed. Fisher’s exact test is used to measure the impact
of patients’ sex, anesthesia type, operation methods, radiation
and malignancy. The c2 test was used for comparison of the
stent sites and obstruction sites. Wilcoxon signed ranks test
was used to compare the changes before and after stent
placement.
3. Results
Among the 23 successfully inserted Resonance metallic
stents, two were removed due to persistent ureteral obstruction
and two due to acute pyelonephritis. The overall patency
maintenance rate was 82.6% (19/23). The patient and disease
characteristics are listed in Table 1. The mean follow-up time
was 5.1 months (range, 0.5e18.2 months). The stent patency
rate did not correlate with sex, stent site, anesthesia method,
obstruction site, disease condition, or operation method. In the
patients receiving radiotherapy, 50% (4/8) had ureteral
obstruction after insertion of the Resonance metallic stent,
and the patency rate was significantly lower than in the non-
radiotherapy group (100%, 15/15, p ¼ 0.008, Table 2).
Stents for malignant obstructions in those other than radio-
therapy patients had a 100% patency rate (5/5).
Stents for benign obstructions in those other than radio-
therapy patients also had a 100% patency rate (10/10). The
four radiotherapy patients with obstructive stents had gyne-
cological diseases (3 cervical and 1 endometrial cancer).
There was no developed stent encrustation found after removal
or change of the stents. Overall, 65.2% (15/23) of the patients
had stent-related symptoms. Abdominal pain accounted for the
majority (5/23, 21.7%), followed by flank pain (3/23, 13%),
bladder pain (3/23, 13%), dysuria (2/23, 8.7%), and acuteTable 2
Patency comparison in different variables
Patent (n ¼ 16) Obstructive (n ¼ 4) p
n (%) n (%)
Sex Female 11 (68.8) 4 (100.0) 0.530a
Male 5 (31.2) 0 (0.0)
Side Left 5 (31.2) 2 (50.0) 0.585b
Right 8 (50.0) 2 (50.0)
Bilateral 3 (18.8) 0 (0.0)
Anesthesia LA 9 (56.2) 2 (50.0) 1.000a
LMA 7 (43.8) 2 (50.0)
Obstruction site UPJ 2 (10.5) 0 (0.0) 0.466b
Upper 3 (15.8) 0 (0.0)
Middle 1 (5.3) 1 (25.0)
Lower 13 (68.4) 3 (75.0)
Disease condition Benign 13 (68.4) 3 (75.0) 1.000a
Malignant 6 (31.6) 1 (25.0)
Operation method Retrograde 18 (94.7) 3 (75.0) 0.380a
Antegrade 1 (5.3) 1 (25.0)
Radiotherapy No 15 (78.9) 0 (0.0) 0.008a
Yes 4 (21.1) 4 (100.0)
Sex, side and anesthesia were counted by patient number, overall n ¼ 20; the
rest of the variables were counted by stent number, overall n ¼ 23. aFisher’s
exact test; bc2 test. LA ¼ local anesthesia; LMA ¼ laryngeal mask anesthesia;
UPJ ¼ ureteropelvic junction.pyelonephritis (2/23, 8.7%). Only two patients reported grade
2 symptoms of dysuria, and the others were all grade 1. Both
of the patients with acute pyelonephritis still had ureteral
obstruction after stent placement and underwent stent removal
after infection. The patients’ variable changes during the stent
procedure between the patent and the obstructive group are
listed in Table 3. Patients in the patent group were younger and
had a longer follow-up period than those in the obstructive
group. Although the pre- and postoperative creatinine changes
did not show statistical significance between the two groups,
patients in the patent group had lower pre- and postoperative
creatinine level and smaller deviation of the creatinine value.
In the patients who received radiotherapy, six had cervical
cancer and two had endometrial cancer. Six (5 cervical and 1
endometrial cancer) patients were in a cancer-free condition.
One patient who had external compression cervical cancer
when the Resonance stent was inserted had stent obstruction
and removal within 1 month. The other patient, who had an
enlarging mass from endometrial cancer, maintained patency
after stent placement. The mode of radiotherapy among these
eight patients varied. In the four obstructive stent patients, two
received three-dimensional conformal radiotherapy and the
other two received intensity-modulated radiation therapy plus
remote afterloading brachytherapy (Table 4).Table 4
Characteristics of gynecological malignancy patients receiving radiotherapy
Patient
no./Age
(yr)
Side Cancer Condition Radiotherapy Patent/obstructive
1/52 Left Endometrial NED IMRTþRAB Obstructive
2/71 Right Cervical NED 3DCRT Obstructive
3/78 Right Endometrial With IMRTþRAB Patent
4/47 Right Cervical NED IMRT þ RAB Patent
5/55 Right Cervical NED 3DCRT Patent
6/71 Left Cervical With IMRT þ RAB Obstructive
7/56 Left Cervical NED IMRT þ RAB Patent
8/77 Right Cervical NED 3DCRT Obstructive
NED ¼ no evidence of disease; IMRT ¼ intensity modulated radiation
therapy; RAB ¼ remote afterloading brachytherapy; 3DCRT ¼ three-dimen-
sional conformal radiotherapy.
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Ureteral obstruction is a common issue among urological
patients. Therapeutic options for releasing the obstruction
include surgical reconstruction, PCN urinary diversion, and
ureteral stents. Treatment selection is based on the disease
etiology, prognosis, quality of life and complications.3 Patients
should be well-informed about the advantages and disadvan-
tages of the therapeutic options and the therapeutic algorithm.
The Resonance metallic stent was designed to afford
compression and intraluminal forces, and has been reported to
have a high patency rate in malignant extrinsic compression.11
In our series, six out of seven ureteral obstructions caused by
malignancy remained patent with the Resonance metallic
stent. The only patient with a failed stent had received
previous radiotherapy. This implied different outcomes using
the Resonance metallic stent between the malignant
extrinsic compression- and radiation-induced ureteral stenosis.
Our result is similar to that of Liatsikos et al, which showed
a good stent response in malignant extrinsic compression.9
However, we found a situation in which metallic stent might
fail in the treatment of post-radiation ureteral stenosis. In the
patients with radiation-induced ureteral stenosis, other treat-
ments such as different kinds of stents, urinary diversion or
surgical reconstruction should also be considered.8
Radiotherapy is important in gynecological malignancies,
and consequent ureteral stenosis complications are not
uncommon.13,14 In our study, all of the patients with previous
radiotherapy had gynecological malignancies, and these
patients had a lower patency rate using the Resonance
metallic stent than the non-radiotherapy group. In addition,
three out of the four patients with failed stents were clinically
cancer-free. These results correspond with those of Liatsikos
et al, although they only mentioned a 44% patency rate in
patients with benign disease and could not identify the specific
failure risk.11
Fujikawa et al have reported a 4.1% ureteral stenosis rate in
the treatment of cervical cancer using external beam radio-
therapy combined with remote afterloading brachytherapy.14
However, our patient group was too small to distinguish the
relationship between radiation mode and ureteral stenosis. In
our analysis, we could not clearly identify why the Reso-
nance stent failed in some patients who had gynecological
malignancies and had received radiotherapy. The total dose
delivered and individual volume of the ureter exposed to the
radiation dosage may play important roles, and they are
difficult for us to control.15 Stent-related complications were
common in our series. Although proper stent size has been
reported to decrease patient discomfort, we found a 65.2% rate
of complicating symptoms after stent placement.16 Three
patients changed stents after 12 months. Only a small amount
of fibrin coating was found on the stents.
In conclusion, the Resonance metallic stent was feasible
and safe for our patients with ureteral obstruction with eithermalignant extrinsic compression or benign intrinsic stenosis.
Gynecological malignancy patients who had previously
received radiotherapy had a significantly lower patency rate
than other non-radiation disease entities.Acknowledgments
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